Menu

GM Study Declared Unsound

A controversial study that suggested genetically modified (GM) maize causes cancer in rats is dismissed by the European Food Safety Authority.

Nov 29, 2012
Jef Akst

Wikimedia, Sreejith KA task force set up by the European Food Safety Authority (EFSA) yesterday (November 28) has confirmed suspicions that a September study claiming to have identified serious health consequences of genetically modified (GM) maize “does not meet acceptable scientific standards.”

The 2-year-long study examined rats fed a Europe- and United States-approved GM corn, called NK603, and claimed they developed massive mammary tumors and died earlier than rats fed conventional corn. The results, which were published in September in Food and Chemical Toxicology, were met with immediate skepticism, leading to an independent evaluation by two French regulatory agencies and the EFSA. Last month (October 4), the EFSA announced its preliminary conclusion that “the design, reporting and analysis of the study, as outlined in the paper, are inadequate.” Now, the agency has declared with more certainty that the study “does not meet acceptable scientific standards, and there is no need to re-examine previous safety evaluations of genetically modified maize NK603.”

The European Union uses millions of tons of GM crops, including NK603 corn, as livestock feed.

(Hat tip to ScienceInsider)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!